MDC & NMD4C Fellowship Funding Awards Coming Soon
The NMD4C in partnership with Muscular Dystrophy Canada (MDC) are excited to share that we will be launching a competition later this year to award funding for two postdoctoral research and two clinical fellowships!
The postdoctoral research fellowship competition will be launched this fall, with the clinical fellowship competition to follow at a later date. The NMD4C and MDC are committed to supporting both early-career researchers and clinicians in building successful careers in neuromuscular disease (NMD) in research and clinical practice.
The postdoctoral research funding opportunity will allow early-career scientists to focus on research contributing to understanding the biological causes and/or new clinical treatment of NMDs. More details about the call for postdoctoral research fellowship applications including eligibility, funding amount, and term will be available soon.
Make sure to stay tuned as we approach the launch of this competition on September 1st, 2021!
[UPDATE] The postdoctoral fellowship funding competition has launched – click here to read more about the fellowship guidelines as well as how to apply.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.